STELLA PHARMA CORPORATION (JP:4888)
:4888
Want to see JP:4888 full AI Analyst Report?
Top Page
STELLA PHARMA CORPORATION
(4888)
Select Model
Select Model
Rating:42Neutral
Price Target:
¥336.00
▲(65.52% Upside)
Action:Reiterated
Date:05/16/26
The score is held down primarily by weak financial performance (persistent losses, sharp revenue volatility, and renewed negative free cash flow in 2026). Technicals are bearish despite oversold readings, and valuation is constrained by unprofitability and the absence of a dividend.
Positive Factors
High gross margins
Consistently high gross margins (roughly 77%–90%) provide structural product-level profitability and pricing power. This margin cushion can support R&D, regulatory activities or commercial investment as revenue recovers, improving the odds of achieving operating leverage without solely relying on cuts.
Negative Factors
Structural unprofitability
Deeply negative operating and net margins (net margin ~ -241%) reflect structural unprofitability. Persistent losses depress returns on equity, consume cash, and force dependence on external financing or material operational improvement to reach sustainable profitability, constraining long-term flexibility.
Read all positive and negative factors
Positive Factors
Negative Factors
High gross margins
Consistently high gross margins (roughly 77%–90%) provide structural product-level profitability and pricing power. This margin cushion can support R&D, regulatory activities or commercial investment as revenue recovers, improving the odds of achieving operating leverage without solely relying on cuts.
Read all positive factors
STELLA PHARMA CORPORATION (4888) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥11.63B
Dividend YieldN/A
Average Volume (3M)332.29K
Price to Earnings (P/E)―
Beta (1Y)0.96
Revenue Growth-66.35%
EPS Growth-409.99%
CountryJP
Employees44
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding35,034,100
10 Day Avg. Volume566,500
30 Day Avg. Volume332,290
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)10.64
Price to Sales (P/S)79.85
P/FCF Ratio-74.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
STELLA PHARMA CORPORATION Business Overview & Revenue Model
Company Description
Stella Pharma Corporation is a pharmaceutical company that handles the complete process of drug development, from research and manufacturing to distribution. A core area of its specialization is in therapeutic agents for boron neutron capture ther...
How the Company Makes Money
Detailed, company-specific information on STELLA PHARMA CORPORATION (4888)’s revenue model (e.g., product portfolio mix, major therapeutic areas, licensing/royalty income, manufacturing/contract services, geographic revenue split, or significant p...
STELLA PHARMA CORPORATION Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
56
Neutral
Cash Flow
35
Negative
| Breakdown | TTM | Mar 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 991.86M | 323.39M | 961.06M | 269.49M | 229.07M | 100.10M |
| Gross Profit | 871.90M | 250.56M | 828.72M | 203.69M | 192.36M | 50.73M |
| EBITDA | -96.70M | -742.15M | -99.06M | -723.85M | -738.35M | -726.86M |
| Net Income | -135.73M | -780.92M | -140.81M | -763.75M | -778.82M | -767.72M |
Balance Sheet | ||||||
| Total Assets | 5.06B | 4.49B | 5.42B | 3.82B | 4.33B | 4.72B |
| Cash, Cash Equivalents and Short-Term Investments | 2.85B | 2.82B | 3.21B | 2.35B | 2.71B | 3.28B |
| Total Debt | 727.12M | 747.14M | 766.78M | 933.30M | 1.09B | 1.25B |
| Total Liabilities | 2.01B | 2.06B | 2.21B | 1.44B | 1.58B | 1.64B |
| Stockholders Equity | 3.05B | 2.43B | 3.21B | 2.38B | 2.75B | 3.08B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -345.32M | 136.50M | -887.82M | -853.07M | -1.13B |
| Operating Cash Flow | 0.00 | -334.51M | 140.41M | -876.84M | -827.67M | -1.08B |
| Investing Cash Flow | 0.00 | -15.67M | 287.58M | -9.01M | -29.93M | -350.56M |
| Financing Cash Flow | 0.00 | -33.28M | 725.78M | 228.25M | 291.69M | 3.46B |
STELLA PHARMA CORPORATION Technical Analysis
Negative
203.00
Price Trends
493.44
Negative
471.05
Negative
390.05
Negative
Market Momentum
-45.86
Negative
36.85
Neutral
69.23
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4888, the sentiment is Negative. The current price of 203 is below the 20-day moving average (MA) of 362.65, below the 50-day MA of 493.44, and below the 200-day MA of 390.05, indicating a bearish trend. The MACD of -45.86 indicates Negative momentum. The RSI at 36.85 is Neutral, neither overbought nor oversold. The STOCH value of 69.23 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4888.
STELLA PHARMA CORPORATION Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | ¥137.76B | -14.35 | ― | 2.18% | -10.48% | -1022.09% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | ¥23.96B | -34.88 | ― | ― | -11.11% | -187.80% | |
45 Neutral | ¥8.15B | -8.57 | -26.70% | ― | 60.80% | -8.89% | |
45 Neutral | ¥17.80B | -10.06 | ― | ― | ― | 6.10% | |
43 Neutral | ¥35.37B | -10.64 | ― | ― | -87.41% | 43.60% | |
42 Neutral | ¥11.63B | -15.42 | ― | ― | -66.35% | -409.99% |
* Healthcare Sector Average
JP:4888
STELLA PHARMA CORPORATION
350.00
-67.00
-16.07%
JP:4571
NanoCarrier Co., Ltd.
105.00
-44.00
-29.53%
JP:4593
Healios KK
273.00
-230.00
-45.73%
JP:4599
StemRIM Inc.
300.00
-37.00
-10.98%
JP:4974
Takara Bio Inc.
1,144.00
364.00
46.67%
JP:7774
Japan Tissue Engineering Co., Ltd.
623.00
3.00
0.48%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.